|
Real-time Estimate
Cboe Europe
19:11:24 28/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 1,721.50 GBX | +1.03% |
|
+3.29% | +11.42% |
| 02:27pm | US estrogen supply crunch widens as women seek alternatives to scarce patches | RE |
| 10-20 | Hikma Pharmaceuticals PLC - Special Call |
| Market Cap | 4.74B 4.25B 3.93B 3.56B 6.65B 450B 6.74B 47.07B 18.7B 236B 17.78B 17.4B 748B | P/E 2026 * |
12.3x | P/E 2027 * | 11x |
|---|---|---|---|---|---|
| Enterprise Value | 6.22B 5.58B 5.16B 4.68B 8.74B 591B 8.85B 61.82B 24.55B 310B 23.36B 22.86B 982B | EV / Sales 2026 * |
1.8x | EV / Sales 2027 * | 1.68x |
| Free-Float |
63.7% | Yield 2026 * |
3.81% | Yield 2027 * | 4.04% |
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| HIK | Delayed | |
CBOE
| HIK | Real-time | |
|
Mexican S.E.
| HIK N | End-of-day quote | |
|
OTC Markets
| HKMPF | Delayed | |
|
Tradegate
| H5P | Real-time | |
|
Boerse Muenchen
| H5P | Real-time | |
|
Deutsche Boerse AG
| H5P | Delayed | |
|
Börse Stuttgart
| H5P | Delayed |
Last Transcript: Hikma Pharmaceuticals PLC
| 1 day | +1.00% | ||
| 1 week | +3.29% | ||
| Current month | +6.74% | ||
| 1 month | +8.48% | ||
| 3 months | +7.07% | ||
| 6 months | +23.62% | ||
| Current year | +11.42% |
| 1 week | 1,645 |  | 1,730 |
| 1 month | 1,557 | | 1,730 |
| Current year | 1,187 | | 1,762 |
| 1 year | 1,187 | | 1,865 |
| 3 years | 1,187 | | 2,360 |
| 5 years | 1,174.5 | | 2,496 |
| 10 years | 814.2 | | 2,768 |
| Manager | Title | Age | Since |
|---|---|---|---|
Said Darwazah
CEO | Chief Executive Officer | 69 | 01/12/2025 |
Areb Kurdi
DFI | Director of Finance/CFO | - | 26/02/2026 |
| Chief Tech/Sci/R&D Officer | 64 | 26/02/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 69 | 14/10/2005 | |
Khalid Nabilsi
BRD | Director/Board Member | 54 | 15/12/2025 |
Said Darwazah
CHM | Chairman | 69 | 15/05/2014 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 01/06/26 | Sell | Investor Relations Manager | -26,558 | 0.0124% | ||
| 01/06/26 | Exercice | Director | 72,763 | 0.0339% | ||
| 01/06/26 | Exercice | Director | 20,650 | 0.0096% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.03% | +3.29% | -2.76% | -9.82% | 4.74B | |
| +0.89% | +2.04% | +58.11% | +129.21% | 1,143B | |
| +1.09% | +5.59% | +45.61% | +85.12% | 647B | |
| +0.51% | +1.29% | +26.78% | +103.31% | 506B | |
| -0.06% | +1.96% | +53.08% | +65.64% | 384B | |
| -0.04% | -5.16% | +63.33% | +38.44% | 350B | |
| +1.10% | +2.81% | +31.93% | +54.13% | 293B | |
| +0.38% | +2.39% | +4.11% | +26.40% | 265B | |
| +1.05% | +3.51% | +55.34% | +72.39% | 242B | |
| +0.67% | +4.59% | +36.26% | +106.54% | 197B | |
| Average | +0.62% | +1.08% | +37.18% | +67.14% | 403.23B | |
| Weighted average by Cap. | +0.66% | +0.71% | +45.39% | +88.05% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.46B 3.1B 2.87B 2.6B 4.86B 329B 4.92B 34.37B 13.65B 172B 12.98B 12.71B 546B | 3.6B 3.23B 2.98B 2.71B 5.06B 342B 5.12B 35.76B 14.2B 179B 13.51B 13.22B 568B |
| Net income | 412M 370M 342M 310M 579M 39.15B 586M 4.1B 1.63B 20.52B 1.55B 1.51B 65.08B | 453M 407M 376M 341M 637M 43.07B 645M 4.51B 1.79B 22.57B 1.7B 1.67B 71.59B |
| Net Debt | 1.48B 1.33B 1.23B 1.12B 2.09B 141B 2.11B 14.75B 5.86B 73.91B 5.57B 5.45B 234B | 1.31B 1.18B 1.09B 985M 1.84B 124B 1.86B 13.02B 5.17B 65.24B 4.92B 4.81B 207B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 28/10/26 | GBX 1,725.00 | +1.23% | 33,610 |
| 27/10/26 | GBX 1,704.00 | +0.24% | 401,978 |
| 26/10/26 | GBX 1,700.00 | +1.43% | 195,462 |
| 23/10/26 | GBX 1,676.00 | -1.06% | 348,452 |
| 22/10/26 | GBX 1,694.00 | +1.32% | 431,134 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- HIK Stock
Select your edition
All financial news and data tailored to specific country editions
